United States Biotechnology & Medical Research

Nuvation Bio Inc (NUVB)

Track

Nuvation Bio Inc. has seen significant insider selling activity over the past 90 days, with multiple officers executing planned and proposed sales. Despite a 43.5% stock price increase over the last quarter and a strong earnings report in May, net insider activity remains negative, offset only by a single purchase of 25,000 shares in June.
Ticker: NUVB Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Nuvation Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Markel Stacy CHIEF PEOPLE OFFICER Officer
Transaction date
Planned sale
Price
232.62
Quantity 97,824 +39.4%
Value US$1,632,456
3.4
Wentworth Kerry CHIEF REGULATORY OFFICER Officer
Transaction date
Planned sale
Price
331.13
Quantity 59,052 -37.3%
Value US$3,489,844
3.4
Sauvage Philippe Chief Financial Officer Officer
Transaction date
Planned sale
Price
390.21
Quantity 71,936 +8.6%
Value US$3,453,006
3.4
KERRY WENTWORTH Officer Officer
Transaction date
Proposed sale
Price
5.76
Quantity 63,000
Value US$362,880
PHILIPPE SAUVAGE Officer Officer
Transaction date
Proposed sale
Price
5.76
Quantity 47,668
Value US$274,568
STACY MARKEL Officer Officer
Transaction date
Proposed sale
Price
5.76
Quantity 125,000
Value US$720,000
3.8
Mashal Robert Non-Executive Director
Transaction date
Purchase
Price
4.73
Quantity 25,000 +12.5%
Value US$118,250
3.4
Wentworth Kerry CHIEF REGULATORY OFFICER Officer
Transaction date
Planned sale
Price
5.01
Quantity 36,750 -40.9%
Value US$184,279
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
5.02
Quantity 50,000 -73.5%
Value US$251,000
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
4.81
Quantity 50,000
Value US$240,500
3.4
KERRY WENTWORTH Officer Officer
Transaction date
Proposed sale
Price
4.81
Quantity 36,750
Value US$176,768
3.4
Wentworth Kerry CHIEF REGULATORY OFFICER Officer
Transaction date
Planned sale
Price
4.52
Quantity 200,000 -79.1%
Value US$903,560
3.4
KERRY WENTWORTH Officer Officer
Transaction date
Proposed sale
Price
4.41
Quantity 200,000
Value US$882,000
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
7.82
Quantity 150,000 -89.3%
Value US$1,173,255
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
7.82
Quantity 150,000
Value US$1,173,255
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
8.00
Quantity 10,000
Value US$80,000
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
8.00
Quantity 10,000 -35.7%
Value US$80,000
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
7.50
Quantity 10,000 -35.7%
Value US$75,000
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
7.50
Quantity 10,000
Value US$75,000
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
7.00
Quantity 20,000 -52.6%
Value US$140,074
2.3
Hattersley Gary CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
7.23
Quantity 300,000 -100.0%
Value US$2,168,100
2.3
Hattersley Gary CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
7.23
Quantity 69,051 -100.0%
Value US$499,032
2.3
GARY HATTERSLEY Officer Officer
Transaction date
Proposed sale
Price
7.23
Quantity 369,051
Value US$2,667,132
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
7.00
Quantity 20,000
Value US$140,074
2.3
Hanley David C. CHIEF TECHNICAL OPERATIONS Officer
Transaction date
Sale
Price
7.14
Quantity 200,000 -89.3%
Value US$1,427,680
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
5.10
Quantity 15,000
Value US$76,552
2.3
DAVID HANLEY Officer Officer
Transaction date
Proposed sale
Price
7.14
Quantity 200,000
Value US$1,427,680
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
5.10
Quantity 15,000 -45.5%
Value US$76,552
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
4.77
Quantity 15,000 -50.0%
Value US$71,475
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
4.77
Quantity 15,000
Value US$71,475
2.3
Hattersley Gary CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Planned sale
Price
5.02
Quantity 100,000 -100.0%
Value US$502,460
2.3
GARY HATTERSLEY Officer Officer
Transaction date
Proposed sale
Price
4.85
Quantity 100,000
Value US$485,000
Markel Stacy CHIEF PEOPLE OFFICER Officer
Transaction date
Planned purchase
Price
1.71
Quantity 10,000 +51.0%
Value US$17,100
3.4
Sauvage Philippe Chief Financial Officer Officer
Transaction date
Purchase
Price
1.79
Quantity 4,000 +67.8%
Value US$7,160
3.4
Wentworth Kerry CHIEF REGULATORY OFFICER Officer
Transaction date
Purchase
Price
1.80
Quantity 24,000 +92.3%
Value US$43,200
3.4
Wentworth Kerry CHIEF REGULATORY OFFICER Officer
Transaction date
Purchase
Price
1.79
Quantity 26,000 +inf%
Value US$46,540
Sjogren Colleen Chief Commercial Officer Officer
Transaction date
Planned purchase
Price
1.81
Quantity 50,000 +161.3%
Value US$90,350
3.4
Sauvage Philippe Chief Financial Officer Officer
Transaction date
Planned purchase
Price
1.84
Quantity 3,300 +126.8%
Value US$6,056
3.6
Hung David PRESIDENT AND CEO Executive Director Large shareholder
Transaction date
Purchase
Price
1.79
Quantity 500,000 +0.9%
Value US$893,500
2.6
Liu Dongfang CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
2.50
Quantity 20,000 -62.5%
Value US$50,024
2.6
DONGFANG LIU Officer Officer
Transaction date
Proposed sale
Price
2.27
Quantity 20,000
Value US$45,400
3.6
Hung David PRESIDENT AND CEO Executive Director Large shareholder
Transaction date
Purchase
Price
1.63
Quantity 300,000 +0.5%
Value US$487,500
3.6
Hung David PRESIDENT AND CEO Executive Director Large shareholder
Transaction date
Purchase
Price
1.66
Quantity 200,000 +0.3%
Value US$332,720
3.8
Mashal Robert Non-Executive Director
Transaction date
Purchase
Price
1.67
Quantity 98,900 +97.8%
Value US$165,153
3.8
Mashal Robert Non-Executive Director
Transaction date
Purchase
Price
1.67
Quantity 1,100 +1.1%
Value US$1,832
3.1
Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. Executive Director
Transaction date
Sale
Price
2.89
Quantity 56,361 -1.4%
Value US$162,883
3.8
Mashal Robert Non-Executive Director
Transaction date
Purchase
Price
2.20
Quantity 99,981 +526215.8%
Value US$219,958
3.8
Mashal Robert Non-Executive Director
Transaction date
Purchase
Price
2.20
Quantity 19 +inf%
Value US$42
3.7
Cui Xiangmin Non-Executive Director
Transaction date
Purchase
Price
2.97
Quantity 277,895 +12.8%
Value US$825,348
3.7
Cui Xiangmin Non-Executive Director
Transaction date
Purchase
Price
2.98
Quantity 336,874 +18.3%
Value US$1,003,885
3.7
Cui Xiangmin Non-Executive Director
Transaction date
Purchase
Price
3.00
Quantity 75,411 +4.3%
Value US$226,233
3.7
Cui Xiangmin Non-Executive Director
Transaction date
Purchase
Price
2.99
Quantity 87,715 +5.2%
Value US$262,268
3.1
BLICKENSTAFF KIM D Non-Executive Director
Transaction date
Purchase
Price
2.90
Quantity 172,189 +inf%
Value US$500,089
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
1.36
Quantity 53,000 +0.4%
Value US$72,138
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
1.36
Quantity 117,100 +0.9%
Value US$159,490
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
1.26
Quantity 5,143,000 +69.9%
Value US$6,460,637
3.1
FALBERG KATHRYN E Non-Executive Director
Transaction date
Purchase
Price
1.95
Quantity 43,000 +20.8%
Value US$83,962
3.1
FALBERG KATHRYN E Non-Executive Director
Transaction date
Purchase
Price
1.98
Quantity 47,000 +29.4%
Value US$93,187
3.1
FALBERG KATHRYN E Non-Executive Director
Transaction date
Purchase
Price
1.97
Quantity 84,959 +113.2%
Value US$167,599
3.1
FALBERG KATHRYN E Non-Executive Director
Transaction date
Purchase
Price
1.85
Quantity 75,041 +inf%
Value US$139,088
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
5.60
Quantity 2,500,000 -10.9%
Value US$14,000,000
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
10.07
Quantity 500,000 -2.1%
Value US$5,035,000
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.80
Quantity 1,400,000 -5.6%
Value US$13,720,000
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
7.69
Quantity 21,758 +1.9%
Value US$167,230
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
7.69
Quantity 163,268 +2.3%
Value US$1,254,862
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.75
Quantity 36 -0.0%
Value US$351
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.76
Quantity 295,000 -1.2%
Value US$2,879,200
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.25
Quantity 2,000,000 -7.4%
Value US$18,500,000
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.27
Quantity 45,000 -0.2%
Value US$417,150
4.2
Omega Fund V, L.P. Large shareholder
Transaction date
Sale
Price
9.60
Quantity 1,015,000 -3.6%
Value US$9,744,000
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Sale
Price
8.64
Quantity 56,598 -4.7%
Value US$489,007
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
8.64
Quantity 56,598 +0.8%
Value US$489,007
3.7
NODELMAN OLEG Non-Executive Director
Transaction date
Purchase
Price
10.45
Quantity 151,544 +2.3%
Value US$1,583,635
3.6
Bazemore Robert B Non-Executive Director
Transaction date
Purchase
Price
9.98
Quantity 5,000 +inf%
Value US$49,900
2.6
EcoR1 Panacea Holdings, LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
10.00
Quantity 390,000 +inf%
Value US$3,900,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-23 PlS Planned sale
Markel Stacy

CHIEF PEOPLE OFFICER

Officer
97,824 +39.4%
232.62
US$1,632,456 		97,824 +39.4% 232.62 US$1,632,456
2026-06-24 2026-06-23 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
59,052 -37.3%
331.13
US$3,489,844 		59,052 -37.3% 331.13 US$3,489,844
2026-06-24 2026-06-23 PlS Planned sale
3.4
Sauvage Philippe

Chief Financial Officer

Officer
71,936 +8.6%
390.21
US$3,453,006 		71,936 +8.6% 390.21 US$3,453,006
2026-06-23 2026-06-23 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
63,000
5.76
US$362,880 		63,000 5.76 US$362,880
2026-06-23 2026-06-23 PrS Proposed sale
PHILIPPE SAUVAGE

Officer

Officer
47,668
5.76
US$274,568 		47,668 5.76 US$274,568
2026-06-23 2026-06-23 PrS Proposed sale
STACY MARKEL

Officer

Officer
125,000
5.76
US$720,000 		125,000 5.76 US$720,000
2026-06-11 2026-06-09 B Purchase
3.8
Mashal Robert
Non-Executive Director
25,000 +12.5%
4.73
US$118,250 		25,000 +12.5% 4.73 US$118,250
2026-04-21 2026-04-17 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
36,750 -40.9%
5.01
US$184,279 		36,750 -40.9% 5.01 US$184,279
2026-04-21 2026-04-17 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
50,000 -73.5%
5.02
US$251,000 		50,000 -73.5% 5.02 US$251,000
2026-04-17 2026-04-17 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
50,000
4.81
US$240,500 		50,000 4.81 US$240,500
2026-04-17 2026-04-17 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
36,750
4.81
US$176,768 		36,750 4.81 US$176,768
2026-04-08 2026-04-06 PlS Planned sale
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
200,000 -79.1%
4.52
US$903,560 		200,000 -79.1% 4.52 US$903,560
2026-04-06 2026-04-06 PrS Proposed sale
3.4
KERRY WENTWORTH

Officer

Officer
200,000
4.41
US$882,000 		200,000 4.41 US$882,000
2025-12-03 2025-12-01 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
150,000 -89.3%
7.82
US$1,173,255 		150,000 -89.3% 7.82 US$1,173,255
2025-12-01 2025-12-01 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
150,000
7.82
US$1,173,255 		150,000 7.82 US$1,173,255
2025-11-26 2025-11-26 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
10,000
8.00
US$80,000 		10,000 8.00 US$80,000
2025-11-26 2025-11-26 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
10,000 -35.7%
8.00
US$80,000 		10,000 -35.7% 8.00 US$80,000
2025-11-26 2025-11-25 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
10,000 -35.7%
7.50
US$75,000 		10,000 -35.7% 7.50 US$75,000
2025-11-25 2025-11-25 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
10,000
7.50
US$75,000 		10,000 7.50 US$75,000
2025-11-24 2025-11-20 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
20,000 -52.6%
7.00
US$140,074 		20,000 -52.6% 7.00 US$140,074
2025-11-24 2025-11-20 S Sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
300,000 -100.0%
7.23
US$2,168,100 		300,000 -100.0% 7.23 US$2,168,100
2025-11-24 2025-11-20 S Sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
69,051 -100.0%
7.23
US$499,032 		69,051 -100.0% 7.23 US$499,032
2025-11-20 2025-11-20 PrS Proposed sale
2.3
GARY HATTERSLEY

Officer

Officer
369,051
7.23
US$2,667,132 		369,051 7.23 US$2,667,132
2025-11-20 2025-11-20 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
20,000
7.00
US$140,074 		20,000 7.00 US$140,074
2025-11-21 2025-11-19 S Sale
2.3
Hanley David C.

CHIEF TECHNICAL OPERATIONS

Officer
200,000 -89.3%
7.14
US$1,427,680 		200,000 -89.3% 7.14 US$1,427,680
2025-11-19 2025-11-19 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
15,000
5.10
US$76,552 		15,000 5.10 US$76,552
2025-11-19 2025-11-19 PrS Proposed sale
2.3
DAVID HANLEY

Officer

Officer
200,000
7.14
US$1,427,680 		200,000 7.14 US$1,427,680
2025-11-19 2025-11-19 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
15,000 -45.5%
5.10
US$76,552 		15,000 -45.5% 5.10 US$76,552
2025-11-19 2025-11-17 S Sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
15,000 -50.0%
4.77
US$71,475 		15,000 -50.0% 4.77 US$71,475
2025-11-17 2025-11-17 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
15,000
4.77
US$71,475 		15,000 4.77 US$71,475
2025-10-29 2025-10-27 PlS Planned sale
2.3
Hattersley Gary

CHIEF SCIENTIFIC OFFICER

Officer
100,000 -100.0%
5.02
US$502,460 		100,000 -100.0% 5.02 US$502,460
2025-10-27 2025-10-27 PrS Proposed sale
2.3
GARY HATTERSLEY

Officer

Officer
100,000
4.85
US$485,000 		100,000 4.85 US$485,000
2025-06-18 2025-06-18 PP Planned purchase
Markel Stacy

CHIEF PEOPLE OFFICER

Officer
10,000 +51.0%
1.71
US$17,100 		10,000 +51.0% 1.71 US$17,100
2025-06-18 2025-06-17 B Purchase
3.4
Sauvage Philippe

Chief Financial Officer

Officer
4,000 +67.8%
1.79
US$7,160 		4,000 +67.8% 1.79 US$7,160
2025-06-18 2025-06-16 B Purchase
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
24,000 +92.3%
1.80
US$43,200 		24,000 +92.3% 1.80 US$43,200
2025-06-18 2025-06-16 B Purchase
3.4
Wentworth Kerry

CHIEF REGULATORY OFFICER

Officer
26,000 +inf%
1.79
US$46,540 		26,000 +inf% 1.79 US$46,540
2025-06-18 2025-06-16 PP Planned purchase
Sjogren Colleen

Chief Commercial Officer

Officer
50,000 +161.3%
1.81
US$90,350 		50,000 +161.3% 1.81 US$90,350
2025-06-18 2025-06-16 PP Planned purchase
3.4
Sauvage Philippe

Chief Financial Officer

Officer
3,300 +126.8%
1.84
US$6,056 		3,300 +126.8% 1.84 US$6,056
2025-06-18 2025-06-16 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
500,000 +0.9%
1.79
US$893,500 		500,000 +0.9% 1.79 US$893,500
2025-05-06 2025-05-02 PlS Planned sale
2.6
Liu Dongfang

CHIEF MEDICAL OFFICER

Officer
20,000 -62.5%
2.50
US$50,024 		20,000 -62.5% 2.50 US$50,024
2025-05-02 2025-05-02 PrS Proposed sale
2.6
DONGFANG LIU

Officer

Officer
20,000
2.27
US$45,400 		20,000 2.27 US$45,400
2025-04-08 2025-04-07 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
300,000 +0.5%
1.63
US$487,500 		300,000 +0.5% 1.63 US$487,500
2025-04-08 2025-04-04 B Purchase
3.6
Hung David

PRESIDENT AND CEO

Executive Director Large shareholder
200,000 +0.3%
1.66
US$332,720 		200,000 +0.3% 1.66 US$332,720
2025-04-03 2025-04-01 B Purchase
3.8
Mashal Robert
Non-Executive Director
98,900 +97.8%
1.67
US$165,153 		98,900 +97.8% 1.67 US$165,153
2025-04-03 2025-04-01 B Purchase
3.8
Mashal Robert
Non-Executive Director
1,100 +1.1%
1.67
US$1,832 		1,100 +1.1% 1.67 US$1,832
2024-11-13 2024-11-11 S Sale
3.1
Wang Junyuan Jerry

CEO, ANHEART THERAPEUTICS LTD.

Executive Director
56,361 -1.4%
2.89
US$162,883 		56,361 -1.4% 2.89 US$162,883
2024-10-10 2024-10-08 B Purchase
3.8
Mashal Robert
Non-Executive Director
99,981 +526215.8%
2.20
US$219,958 		99,981 +526215.8% 2.20 US$219,958
2024-10-10 2024-10-08 B Purchase
3.8
Mashal Robert
Non-Executive Director
19 +inf%
2.20
US$42 		19 +inf% 2.20 US$42
2024-06-26 2024-06-25 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
277,895 +12.8%
2.97
US$825,348 		277,895 +12.8% 2.97 US$825,348
2024-06-25 2024-06-24 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
336,874 +18.3%
2.98
US$1,003,885 		336,874 +18.3% 2.98 US$1,003,885
2024-06-25 2024-06-21 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
75,411 +4.3%
3.00
US$226,233 		75,411 +4.3% 3.00 US$226,233
2024-06-25 2024-06-20 B Purchase
3.7
Cui Xiangmin
Non-Executive Director
87,715 +5.2%
2.99
US$262,268 		87,715 +5.2% 2.99 US$262,268
2024-06-13 2024-06-11 B Purchase
3.1
BLICKENSTAFF KIM D
Non-Executive Director
172,189 +inf%
2.90
US$500,089 		172,189 +inf% 2.90 US$500,089
2023-09-21 2023-02-21 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
53,000 +0.4%
1.36
US$72,138 		53,000 +0.4% 1.36 US$72,138
2023-09-21 2023-02-20 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
117,100 +0.9%
1.36
US$159,490 		117,100 +0.9% 1.36 US$159,490
2023-09-21 2023-02-19 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
5,143,000 +69.9%
1.26
US$6,460,637 		5,143,000 +69.9% 1.26 US$6,460,637
2022-12-05 2022-12-05 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
43,000 +20.8%
1.95
US$83,962 		43,000 +20.8% 1.95 US$83,962
2022-12-05 2022-12-02 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
47,000 +29.4%
1.98
US$93,187 		47,000 +29.4% 1.98 US$93,187
2022-12-05 2022-12-01 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
84,959 +113.2%
1.97
US$167,599 		84,959 +113.2% 1.97 US$167,599
2022-12-05 2022-11-30 B Purchase
3.1
FALBERG KATHRYN E
Non-Executive Director
75,041 +inf%
1.85
US$139,088 		75,041 +inf% 1.85 US$139,088
2022-04-07 2022-04-05 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
2,500,000 -10.9%
5.60
US$14,000,000 		2,500,000 -10.9% 5.60 US$14,000,000
2021-12-17 2021-12-15 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
500,000 -2.1%
10.07
US$5,035,000 		500,000 -2.1% 10.07 US$5,035,000
2021-12-09 2021-12-07 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
1,400,000 -5.6%
9.80
US$13,720,000 		1,400,000 -5.6% 9.80 US$13,720,000
2021-11-30 2021-11-24 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
21,758 +1.9%
7.69
US$167,230 		21,758 +1.9% 7.69 US$167,230
2021-11-30 2021-11-24 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
163,268 +2.3%
7.69
US$1,254,862 		163,268 +2.3% 7.69 US$1,254,862
2021-11-24 2021-11-23 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
36 -0.0%
9.75
US$351 		36 -0.0% 9.75 US$351
2021-11-24 2021-11-22 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
295,000 -1.2%
9.76
US$2,879,200 		295,000 -1.2% 9.76 US$2,879,200
2021-11-05 2021-11-03 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
2,000,000 -7.4%
9.25
US$18,500,000 		2,000,000 -7.4% 9.25 US$18,500,000
2021-11-01 2021-10-29 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
45,000 -0.2%
9.27
US$417,150 		45,000 -0.2% 9.27 US$417,150
2021-11-01 2021-10-28 S Sale
4.2
Omega Fund V, L.P.
Large shareholder
1,015,000 -3.6%
9.60
US$9,744,000 		1,015,000 -3.6% 9.60 US$9,744,000
2021-11-30 2021-07-31 S Sale
3.7
NODELMAN OLEG
Non-Executive Director
56,598 -4.7%
8.64
US$489,007 		56,598 -4.7% 8.64 US$489,007
2021-11-30 2021-07-31 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
56,598 +0.8%
8.64
US$489,007 		56,598 +0.8% 8.64 US$489,007
2021-11-30 2021-03-31 B Purchase
3.7
NODELMAN OLEG
Non-Executive Director
151,544 +2.3%
10.45
US$1,583,635 		151,544 +2.3% 10.45 US$1,583,635
2021-04-01 2021-03-30 B Purchase
3.6
Bazemore Robert B
Non-Executive Director
5,000 +inf%
9.98
US$49,900 		5,000 +inf% 9.98 US$49,900
2020-07-06 2020-07-06 B Purchase
2.6
EcoR1 Panacea Holdings, LLC
Non-Executive Director Large shareholder
390,000 +inf%
10.00
US$3,900,000 		390,000 +inf% 10.00 US$3,900,000
Explore more

More insider trading research around Nuvation Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America